Efficacy and Safety of Lixisenatide Versus Insulin Glulisine on Top of Insulin Glargine With or Without Metformin in Type 2 Diabetic Patients

A phase 3 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 894 participants.

Also called NCT01768559

  • Study
  • In this atlas

Overview

Design
Interventional study; randomized; no masking; primary purpose treatment
Phase
Phase 3
Enrolled
  • 894 participants (enrolled count) (from the registry)
Sponsor
  • Sanofi Registry lists this organization as the lead sponsor
Registry
  • NCT NCT01768559
  • EudraCT 2012-004096-38
Main results
  • Prandial Options to Advance Basal Insulin Glargine Therapy: Testing Lixisenatide Plus Basal Insulin Versus Insulin Glulisine Either as Basal-Plus or Basal-Bolus in Type 2 Diabetes: The GetGoal Duo-2 Trial Diabetes care, 2016-08 DOI, PubMed 27222510

Courtesy of the U.S. National Library of Medicine.

Start date
(registry gives no type) (from the registry)
Primary completion
(actual) (from the registry)
Completion
(actual) (from the registry)
Results first posted
(from the registry)
Countries
United States, Canada, Chile, Czechia, Estonia, France, Germany, Hungary, Italy, Latvia, Lithuania, Mexico, Poland, Romania, Russia, Spain, Ukraine, United Kingdom (from the registry)
Registry status
  • Completed (from the registry)

Technical summary

Registry record NCT01768559. Randomized; no masking; primary purpose treatment. Start 2013-01 (registry gives no type); primary completion 2014-12 (actual). Results posted on 2017-01-04.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
Efficacy and Safety of Lixisenatide Versus Insulin Glulisine on Top of Insulin Glargine With or Without Metformin in Type 2 Diabetic Patients
Acronym
GetGoal-Duo-2
Intervention (Drug)
Lixisenatide (AVE0010)
Intervention (Drug)
Insulin glulisine QD
Intervention (Drug)
Insulin glulisine TID
Intervention (Drug)
Insulin Glargine (Mandatory background drug)
Intervention (Drug)
Metformin (Background drug)
Lead sponsor
Sanofi (class: industry)

Record details

Record id
cardio:ct-nct01768559
Content hash
eed81416351900916398ffe8b010ac8dc22d48bcef2eeaa1324643ab8efb442b